Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 57, Issue 1, 2018, Pages 164-174

  Nakayamada, Shingo ^a   Kubo, Satoshi ^a   Yoshikawa, Maiko ^a   Miyazaki, Yusuke ^a   Yunoue, Naoki ^a   Iwata, Shigeru ^a   Miyagawa, Ippei ^a   Hirata, Shintaro ^a   Nakano, Kazuhisa ^a   Saito, Kazuyoshi ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

biologic DMARDs; immunophenotype; plasmablasts; rheumatoid arthritis; T follicular helper cells

Indexed keywords

ABATACEPT; ADALIMUMAB; AUTOANTIBODY; CD27 ANTIGEN; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN D; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DAS28; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMABLAST; PLASMACYTOID DENDRITIC CELL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; TFH CELL; TH17 CELL; THERAPY EFFECT; AGED; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; DENDRITIC CELL; HELPER CELL; IMMUNOLOGY; RETROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION;

ABATACEPT; ADALIMUMAB; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CERTOLIZUMAB PEGOL; DENDRITIC CELLS; ETANERCEPT; FEMALE; HUMANS; IMMUNOGLOBULIN D; IMMUNOPHENOTYPING; INFLIXIMAB; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 7; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85039058514     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex012     Document Type: Article

References (39)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11.
2. Herman S, Kronke G, Schett G. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 2008;14:245-53.
3. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol 2012;12:191-200.
4. Furst DE, Emery P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology 2014;53:1560.
5. Lubberts E, Koenders MI, Oppers-Walgreen B et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-9.
6. Komatsu N, Takayanagi H. Autoimmune arthritis: the interface between the immune system and joints. Adv Immunol 2012;115:45-71.
7. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity 2014;41:529-42.
8. Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular helper T cells. Annu Rev Immunol 2016;34:335-68.
9. Nakayamada S, Kanno Y, Takahashi H et al. Early Th1 cell differentiation is marked by a Tfh cell-like transition. Immunity 2011;35:919-31.
10. Kobezda T, Ghassemi-Nejad S, Mikecz K, Glant TT, Szekanecz Z. Of mice and men: how animal models advance our understanding of T-cell function in RA. Nat Rev Rheumatol 2014;10:160-70.
11. Nakayamada S, Takahashi H, Kanno Y, O'Shea JJ. Helper T cell diversity and plasticity. Curr Opin Immunol 2012;24:297-302.
12. Smolen JS, Schoels MM, Nishimoto N et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013;72:482-92.
13. Smolen JS, Redlich K, Zwerina J et al. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin Rev Allergy Immunol 2005;28:239-48.
14. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
15. Nagafuchi Y, Shoda H, Sumitomo S et al. Immunophenotyping of rheumatoid arthritis reveals a linkage between HLA-DRB1 genotype, CXCR4 expression on memory CD4(+) T cells, and disease activity. Sci Rep 2016;6:29338
16. Ermann J, Rao DA, Teslovich NC, Brenner MB, Raychaudhuri S. Immune cell profiling to guide therapeutic decisions in rheumatic diseases. Nat Rev Rheumatol 2015;11:541-51.
17. Liu R, Wu Q, Su D et al. A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. Arthritis Res Ther 2012;14:R255
18. Ma J, Zhu C, Ma B et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin Dev Immunol 2012;2012:827480
19. Metawi SA, Abbas D, Kamal MM, Ibrahim MK. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 2011;30:1201-7.
20. Suurmond J, Dorjee AL, Boon MR et al. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 2011;13:R150
21. Tiburzy B, Kulkarni U, Hauser AE, Abram M, Manz RA. Plasma cells in immunopathology: concepts and therapeutic strategies. Semin Immunopathol 2014;36:277-88.
22. Khoder A, Sarvaria A, Alsuliman A et al. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood 2014;124:2034-45.
23. Richez C, Schaeverbeke T, Dumoulin C et al. Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab. Arthritis Res Ther 2009;11:R100
24. Jongbloed SL, Lebre MC, Fraser AR et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Thr 2006;8:R15
25. Takakubo Y, Takagi M, Maeda K et al. Distribution of myeloid dendritic cells and plasmacytoid dendritic cells in the synovial tissues of rheumatoid arthritis. J Rheumatol 2008;35:1919-31.
26. Platt AM, Gibson VB, Patakas A et al. Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010;185:1558-67.
27. Iwata S, Nakayamada S, Fukuyo S et al. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. Arthritis Rheumatol 2015;67:63-73.
28. Scarsi M, Paolini L, Ricotta D et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol 2014;41:666-72.
29. Emery P, Durez P, Dougados M et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510-6.
30. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011;70:4-7.
31. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 2005;102:3372-7.
32. Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008;19:41-52.
33. Nakayamada S, Poholek AC, Lu KT et al. Type I interferon induces binding of STAT1 to Bcl6: Divergent roles of STAT-family transcription factors in the TFH cell genetic program. J Immunol 2014;192:2156-66.
34. Swiecki M, Wang Y, Vermi W et al. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med 2011;208:2367-74.
35. Mahmood Z, Muhammad K, Schmalzing M et al. CD27- IgD-memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis. Arthritis Res Ther 2015;17:61
36. Adlowitz DG, Barnard J, Biear JN et al. Expansion of activated peripheral blood memory B cells in rheumatoid arthritis, impact of B cell depletion therapy, and biomarkers of response. PLoS One 2015;10:e0128269
37. Samson M, Audia S, Janikashvili N et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2499-503.
38. Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol 2013;171:237-42.
39. Thiolat A, Semerano L, Pers YM et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol 2014;66:273-83.